<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="medium, provided the original work is properly cited. Abstract The" exact="treatment" post="of inflammatory bowel disease (IBD) has been revolutionized for"/>
 <result pre="of immunomodulators and biologics. With immunosuppression of this kind, opportunistic" exact="infection" post="is an important safety concern for patients with IBD."/>
 <result pre="IBD. Inflammatory bowel disease Viral hepatitis Vaccination Prevention INTRODUCTION The" exact="treatment" post="of IBD has been revolutionized over the past decade"/>
 <result pre="of immunomodulators and biologics. With immunosuppression of this kind, opportunistic" exact="infection" post="becomes a key safety concern in patients with IBD"/>
 <result pre="show intermediate endemicity for the HAV, while HBV shows moderate" exact="prevalence" post="compared with United States and Western Europe. Thus, members"/>
 <result pre="patients with IBD. We focused on prevention and monitoring, and" exact="treatment" post="of viral hepatitis are not included in this guideline."/>
 <result pre="by poor hygiene, and contaminated food or drink [17,18]. HAV" exact="infection" post="is usually a self-limiting illness that does not become"/>
 <result pre="that does not become chronic, unlike HBV or HCV. Instead," exact="infection" post="confers lifelong immunity and is preventable via vaccination. Furthermore,"/>
 <result pre="develops into acute fulminant hepatitis, which can cause death. HAV" exact="infection" post="is prevalent around the world, but it shows various"/>
 <result pre="low endemicity (such as the United States and Western Europe)," exact="infection" post="is less frequent, but the disease does occur among"/>
 <result pre="disease, those with clotting factor disorders, and those in direct" exact="contact" post="with others who have hepatitis A. Patients with IBD"/>
 <result pre="disease [21]. In HAV, IgG antibodies appear early in the" exact="infection" post="phase and remain throughout the patient’s life, preventing disease."/>
 <result pre="patient’s life, preventing disease. The decision to pursue prevaccination serological" exact="testing" post="in adults should be based on the expected prevalence"/>
 <result pre="serological testing in adults should be based on the expected" exact="prevalence" post="of immunity within the given population, as well as"/>
 <result pre="economic development in Korea, a rapid epidemiological shift in HAV" exact="infection" post="has occurred [20,23]. Most adults had immunity to HAV"/>
 <result pre="is absent [22]. In patients with IBD, we recommend HAV" exact="testing" post="(IgG antiHAV antibody) in patients with no history of"/>
 <result pre="about contaminated food and water. In general, routine anti-HAV IgG" exact="testing" post="is not necessary after vaccination, since the seroconversion rate"/>
 <result pre="liver cirrhosis, or hepatocellular carcinoma. Both acute and chronic HBV" exact="infection" post="may be accompanied by extrahepatic symptoms. The prevalence of"/>
 <result pre="chronic HBV infection may be accompanied by extrahepatic symptoms. The" exact="prevalence" post="of the virus varies by country and region, from"/>
 <result pre="by country and region, from 2% in countries with low" exact="prevalence" post="(e.g., UK, Canada, Western Europe, etc.), 2%–7% in those"/>
 <result pre="UK, Canada, Western Europe, etc.), 2%–7% in those with moderate" exact="prevalence" post="(e.g., South Korea, Mediterranean countries, Japan, Central Asia, Middle"/>
 <result pre="in West Africa and South Sudan, which have the highest" exact="prevalence" post="rates [37,38]. In Korea, HBV vaccination of all newborns"/>
 <result pre="in 2001, and 0.3% in 2016. In IBD patients, the" exact="prevalence" post="of chronic HBV infection (positive HBsAg, positive anti-HBc, and"/>
 <result pre="in 2016. In IBD patients, the prevalence of chronic HBV" exact="infection" post="(positive HBsAg, positive anti-HBc, and negative anti-HBs) was 3.8%"/>
 <result pre="HBsAg, positive anti-HBc, and negative anti-HBs) was 3.8% and past" exact="infection" post="(negative HBsAg, positive anti-HBc, and positive or negative anti-HBs)"/>
 <result pre="[41]. The World Health Organization (WHO) has estimated that the" exact="prevalence" post="of chronic hepatitis B infection in children under 5"/>
 <result pre="(WHO) has estimated that the prevalence of chronic hepatitis B" exact="infection" post="in children under 5 years will be 1% in"/>
 <result pre="Therefore, all patients with IBD should be assessed for HBV" exact="infection" post="(HBsAg, anti-HBs, anti-HBc) or immunization status. Patients who are"/>
 <result pre="start immunosuppressive therapy who are either HBsAg-positive or anti-HBc-positive at" exact="diagnosis" post="[3]. The role of anti-HBs screening before immunosuppressive therapy"/>
 <result pre="HBsAg-positive or anti-HBc-positive at diagnosis [3]. The role of anti-HBs" exact="screening" post="before immunosuppressive therapy remains unclear, and the presence of"/>
 <result pre="anti-HBs does not imply prevention of HBV reactivation. However, anti-HBs" exact="testing" post="may be helpful for detecting past infection in patients"/>
 <result pre="reactivation. However, anti-HBs testing may be helpful for detecting past" exact="infection" post="in patients who are HBsAg-negative and anti-HBc-positive. Furthermore, loss"/>
 <result pre="or unclear HBV vaccination history at the time of IBD" exact="diagnosis" post="(strong recommendation, high level of evidence). · Level of"/>
 <result pre="agree 20%, uncertain 5%, disagree 0%, strongly disagree 2.5% The" exact="prevalence" post="of HBV in patients with IBD is not different"/>
 <result pre="whether universal vaccination is necessary in areas with low HBV" exact="prevalence" post="[54,55]. The WHO recommended administering the HBV vaccine after"/>
 <result pre="12% of patients were administered HBV vaccine [53]. Since HBV" exact="infection" post="is relatively common in Korea, specific attention should be"/>
 <result pre="in Korea, specific attention should be given to HBV serology" exact="testing" post="and HBV vaccination in patients with IBD. It is"/>
 <result pre="cause of isolated anti-HBc positive cases in areas with high" exact="prevalence" post="of hepatitis B, such as Korea, is past HBV"/>
 <result pre="However, in patients who require immunosuppression from the time of" exact="diagnosis" post="of IBD, HBV vaccination could be administered with commencement"/>
 <result pre="[66]. Statement 5 Patients with IBD require to undergo serology" exact="testing" post="1 to 3 months after administration of the last"/>
 <result pre="to oral cholera vaccine [70]. In healthy individuals, routine immunity" exact="testing" post="after vaccination is not necessary. However, in the patients"/>
 <result pre="is not necessary. However, in the patients with IBD, whose" exact="treatment" post="depends on immune status, serology testing 1 to 3"/>
 <result pre="patients with IBD, whose treatment depends on immune status, serology" exact="testing" post="1 to 3 months after administration of the last"/>
 <result pre="are administered if anti-HBs &amp;lt; 10 mIU/mL. Then HBV serology" exact="testing" post="should be performed 1 to 2 months after completion"/>
 <result pre="reactivation is classified as follows: (1) exacerbation of chronic HBV" exact="infection" post="in patients who are HBsAg-positive, or (2) relapse of"/>
 <result pre="patients who are HBsAg-positive, or (2) relapse of past HBV" exact="infection" post="in patients who are HBsAg-negative plus anti-HBc-positive [80]. Exacerbation"/>
 <result pre="who are HBsAg-negative plus anti-HBc-positive [80]. Exacerbation of chronic HBV" exact="infection" post="is defined as a more than a 100-fold rise"/>
 <result pre="among patients who are HBsAg-positive [3]. Relapse of past HBV" exact="infection" post="is detected based on reverse seroconversion (seroreversion) from HBsAg-negativity"/>
 <result pre="reverse seroconversion (seroreversion) from HBsAg-negativity to HBsAg-positivity, or on the" exact="detection" post="of serum HBV DNA in patients who are HBsAg-negative"/>
 <result pre="prophylaxis should be considered on a case-by-case basis, considering comorbidities," exact="prevalence" post="of anti-HBc positivity, and health care resources [5]. However,"/>
 <result pre="is constantly associated with hepatitis flare-ups, even though HBV DNA" exact="detection" post="leads to seroreversion and hepatitis in only 50% of"/>
 <result pre="in HBV DNA, both during and after immunosuppressive therapy. Antiviral" exact="treatment" post="should be started in cases of detectable HBV DNA"/>
 <result pre="seroreversion [6]. HEPATITIS C VIRUS 1. Epidemiology The global HCV" exact="prevalence" post="is estimated at 2.5% (177.5 million of HCV-infected adults),"/>
 <result pre="1.3% in the Americas [119]. In the early 1990s, the" exact="prevalence" post="of HCV was reported as 1.7% by enzyme immunoassay"/>
 <result pre="by enzyme immunoassay method among Korean individuals who underwent health" exact="screening" post="program [120]. More recently, a nationwide seroepidemiology study demonstrated"/>
 <result pre="≥ 70 years, respectively [121]. A high-risk group for HCV" exact="infection" post="includes individuals who inject drugs, patients who undergo dialysis,"/>
 <result pre="reported relatively infrequently [2]. 2. Screening Statement 9 We recommend" exact="testing" post="newly diagnosed patients with IBD for IgG anti-HCV antibody."/>
 <result pre="positive, HCV RNA titer should be checked to confirm HCV" exact="infection" post="(strong for recommendation, moderate level of evidence). · Level"/>
 <result pre="of IBD diagnosis. When IgG anti-HCV antibody is detected by" exact="screening" post="[125], the patients’ HCV RNA titer should be tested"/>
 <result pre="patients’ HCV RNA titer should be tested to confirm HCV" exact="infection" post="[126]. If infection is confirmed, patients should be treated"/>
 <result pre="titer should be tested to confirm HCV infection [126]. If" exact="infection" post="is confirmed, patients should be treated according to the"/>
 <result pre="to the HCV clinical practice guidelines [7]. If possible, HCV" exact="infection" post="should be treated before biologic treatments of IBD are"/>
 <result pre="treated using TNF-α inhibitor, mainly for rheumatoid arthritis, worsening HCV" exact="infection" post="was identified in only one patient [124]. The benefits"/>
 <result pre="However, based on current existing evidence, we cannot recommend simultaneous" exact="treatment" post="of IBD (using a TNF-α inhibitor) and HCV infection."/>
 <result pre="reduce drug efficacy [7]. CONCLUSION In patients with IBD, opportunistic" exact="infection" post="is a key safety concern with the increasing use"/>
 <result pre="management of viral hepatitis in IBD will prevent hepatitis viral" exact="infection" post="and reactivation, and that it will lessen confusion among"/>
 <result pre="AsiaIntest Res20191728531031146509 2RahierJFMagroFAbreuCet al.Second European evidencebased consensus on the prevention," exact="diagnosis" post="and management of opportunistic infections in inflammatory bowel diseaseJ"/>
 <result pre="European Association for the Study of the LiverEASL recommendations on" exact="treatment" post="of hepatitis C 2018J Hepatol20186946151129650333 8TerraultNALokASFMcMahonBJet al.Update on prevention,"/>
 <result pre="hepatitis C 2018J Hepatol20186946151129650333 8TerraultNALokASFMcMahonBJet al.Update on prevention, diagnosis, and" exact="treatment" post="of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology2018671560159929405329"/>
 <result pre="Liver (KASL)2017 KASL clinical practice guidelines management of hepatitis C:" exact="treatment" post="of chronic hepatitis CClin Mol Hepatol20182416922930092624 10collab: Korean Association"/>
 <result pre="Hepatol2019259315931185710 11SinghJASaagKGBridgesSLJret al.2015 American College of Rheumatology Guideline for the" exact="treatment" post="of rheumatoid arthritisArthritis Care Res (Hoboken)20166812526545825 12RubinLGLevinMJLjungmanPet al.2013 IDSA"/>
 <result pre="estimates of age-specific HBsAg seroprevalence and endemicityVaccine2012302212221922273662 37SchweitzerAHornJMikolajczykRTKrauseGOttJJEstimations of worldwide" exact="prevalence" post="of chronic hepatitis B virus infection: a systematic review"/>
 <result pre="Accessed Dec 31, 2019 41YeoSJLeeHSJangBIet al.Nonimmunity against hepatitis B virus" exact="infection" post="in patients newly diagnosed with inflammatory bowel diseaseIntest Res20181640040830090039"/>
 <result pre="comprehensive immunization strategy to eliminate transmission of hepatitis B virus" exact="infection" post="in the United States: recommendations of the Advisory Committee"/>
 <result pre="children with hematological malignanciesHematol J2003432132714502256 94ChungSJKimJKParkMCParkYBLeeSKReactivation of hepatitis B viral" exact="infection" post="in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapyJ"/>
 <result pre="prophylaxisGut2004531363136515306601 96KimYJBaeSCSungYKet al.Possible reactivation of potential hepatitis B virus occult" exact="infection" post="by tumor necrosis factor-alpha blocker in the treatment of"/>
 <result pre="virus occult infection by tumor necrosis factor-alpha blocker in the" exact="treatment" post="of rheumatic diseasesJ Rheumatol20103734635020008922 97ParkSHYangSKLimYSet al.Clinical courses of chronic"/>
 <result pre="diseasesJ Rheumatol20103734635020008922 97ParkSHYangSKLimYSet al.Clinical courses of chronic hepatitis B virus" exact="infection" post="and inflammatory bowel disease in patients with both diseasesInflamm"/>
 <result pre="Dis2012182004201022337144 98PerrilloRPGishRFalck-YtterYTAmerican Gastroenterological Association Institute technical review on prevention and" exact="treatment" post="of hepatitis B virus reactivation during immunosuppressive drug therapyGastroenterology201514822124425447852"/>
 <result pre="Gastroenterological AssociationInstituteAmerican Gastroenterological Association Institute guideline on the prevention and" exact="treatment" post="of hepatitis B virus reactivation during immunosuppressive drug therapyGastroenterology201514821521925447850"/>
 <result pre="Med Sci199273333361284374 121KimDYKimIHJeongSHet al.A nationwide seroepidemiology of hepatitis C virus" exact="infection" post="in South KoreaLiver Int20133358659423356674 122collab: Korean Association for the"/>
 <result pre="hepatitis CClin Mol Hepatol2014208913625032178 123HellardMSacks-DavisRDoyleJHepatitis C elimination by 2030 through" exact="treatment" post="and prevention: think global, act in local networksJ Epidemiol"/>
 <result pre="with chronic hepatitis C infection: a systematic reviewRheumatology (Oxford)2011501700171121690185 125PawlotskyJMMolecular" exact="diagnosis" post="of viral hepatitisGastroenterology20021221554156812016423 126VermehrenJYuMLMontoAet al.Multi-center evaluation of the Abbott"/>
 <result pre="et al. [2] Second European evidence-based consensus on the prevention," exact="diagnosis" post="and management of opportunistic infections in inflammatory bowel disease"/>
 <result pre="clinical practice guidelines on the management of hepatitis B virus" exact="infection" post="Europe Journal of Hepatology 2017 67/370-398 European Association for"/>
 <result pre="for the Study of the Liver [7] EASL recommendations on" exact="treatment" post="of hepatitis C 2018 Europe Journal of Hepatology 2018"/>
 <result pre="69/461-511 Terrault et al. [8] Update on prevention, diagnosis, and" exact="treatment" post="of chronic hepatitis B: AASLD 2018 hepatitis B guidance"/>
 <result pre="[9] 2017 KASL clinical practice guidelines management of hepatitis C:" exact="treatment" post="of chronic hepatitis C Korea Clin Mol Hepatol 2018"/>
 <result pre="al. [11] 2015 American College of Rheumatology guideline for the" exact="treatment" post="of rheumatoid arthritis USA Arthritis Care &amp;amp; Research 2016"/>
</results>
